Identifying new biomarkers for clear cell renal cell carcinoma
Official title: Novel Biomarkers of Hypoxia and Metabolism in Clear Cell Renal Cell Carcinoma
Run by Qianfoshan Hospital · NCT05214885 · Data updated 2026-11-12
This study is trying to find new markers in the blood that can help doctors diagnose clear cell kidney cancer earlier and better by comparing them in patients with the cancer and healthy people.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 300 (estimated) |
| Sponsor | Qianfoshan Hospital Academic / other |
| Locations | 1 site (Jinan) |
| Status | Recruiting |
| Started | February 11, 2022 |
| Main results expected | December 31, 2025 |
| Study ends | December 31, 2026 |
| Registry record updated | March 9, 2022 |
| Trial ID | NCT05214885 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients diagnosed with clear cell renal cell carcinoma and healthy individuals matched by age and sex.
✕Probably not a fit
Patients with other types of tumors or significant renal or systemic diseases may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to identify novel biomarkers related to hypoxia and metabolism in patients with clear cell renal cell carcinoma (ccRCC). By analyzing the expression of specific molecules, such as carbonic anhydrase IX and others, the study seeks to improve early diagnosis and understanding of ccRCC. The research involves comparing these biomarkers in ccRCC patients to healthy controls to establish their potential as reliable diagnostic tools. No interventions are required from participants, making it a non-invasive study.
Why it matters
Potential benefit: If successful, this study could lead to earlier diagnosis and better management of clear cell renal cell carcinoma.
How similar studies have gone: Preliminary studies have suggested that similar approaches to identifying biomarkers in ccRCC have shown promise, indicating potential for success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * The age and sex of the healthy control group were matched with that of ccRCC patient group. There was no tumor in the kidney or other parts of the body, and no tumor in the blood system. The healthy control group did not have any renal benign diseases, such as kidney stones, diabetic nephropathy, inflammation, and uremia. There are no inflammatory diseases in other parts of the body; the functions of the liver, kidney, and heart were normal. Exclusion Criteria: * The volunteer has tumors in the kidney or other parts of the body, or blood system tumors; The volunteer has benign kidney diseases, such as kidney stones, diabetic nephropathy, nephritis and uremia, etc; The patient has inflammatory disease elsewhere. If the volunteer has any one of the above diseases, it shall be excluded.
Where it's running
-
The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital
Jinan, China Recruiting
Study contacts
- Principal investigator: Li Zhang, Dr. — The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital
- Study coordinator: Li Zhang, Dr.
- Email: maggie_zhangli@139.com
- Phone: +86-531-89269680
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Cadonilimab and Lenvatinib in advanced kidney cancer
This study tests whether Cadonilimab plus Lenvatinib can help adults with unresectable, advanced renal cell carcinoma, especially clear cell type, after prior treatments.
-
CAIX-targeted PET/CT imaging in solid tumors
Researchers are testing a CAIX-targeted PET/CT imaging agent to see if it detects and reflects CAIX levels in solid tumors like clear cell renal cell carcinoma, NSCLC, and breast cancer.
-
Immune cell therapy for advanced clear cell kidney cancer
This study tests a patient's own tumor-infiltrating lymphocytes (TIL) therapy, given after conditioning with chemotherapy and then interleukin-2, in adults with advanced clear cell renal cell carcinoma who have tried prior treatments.
-
Theranostic pair labeled PD-32766D/T in CA9-positive clear cell kidney cancer
This study tests a matching diagnostic agent PD-32766D and a therapeutic agent PD-32766T in adults with CA9-expressing clear cell renal cell carcinoma to see if the treatment is safe and shows signs of effect.
-
LNK001 CAR T therapy in advanced clear cell kidney cancer
This study tests a CAR T-cell therapy called LNK001 to see if it can help people with advanced clear cell renal cell carcinoma after other treatments.
-
Neoadjuvant immunotherapy with botensilimab and balstilimab for high-risk non-metastatic clear cell RCC
This trial tests whether giving botensilimab and balstilimab before kidney tumor surgery is safe and helps patients with high‑risk non‑metastatic clear cell RCC proceed to nephrectomy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.